Prof. Steve Kerrigan currently holds the position of Chair/Full Professor and Deputy Head of the School of Pharmacy and Biomolecular Sciences in RCSI University of Medicine and Health Sciences. Since his faculty appointment, he has published almost 100 articles in high impact peer-reviewed international journals, filed 10 patent/invention disclosures, supervised 21 multidisciplinary doctoral candidates as primary supervisor and spun out a life sciences company. He has extensive experience in acquiring research funding from various grant awarding bodies including HRB, SFI, EI, Wellcome Trust, NIH (USA) as well as significant industry funding. He is currently co-chair of the International Society for Thrombosis and Haemostasis Scientific Standardization Committee and committee member in the European Sepsis Alliance research committee. He is also involved in significant innovation and commercialization of his research. Prof. Kerrigan identified a novel drug target for the treatment of severe bloodstream infection/sepsis/COVID-19. His drug has successfully completed preclinical and Phase I clinical trials and is preparing for a Phase IIb human clinical trial. Recently he co-founded an RCSI spinout company, Inthelia Therapeutics Ltd of which he is Chief Scientific Officer to further develop the opportunity. Prof. Kerrigan is extensively involved in Public Engagement and Outreach Activities. He is currently the Academic Director of the MyHealth Public Engagement Programme in RCSI. This programme crosses the full spectrum of ages from primary school children to teenagers and adults with the sole objective to empower the public to take ownership of their own health and well being.